111 related articles for article (PubMed ID: 16838651)
1. [Malignant melanoma].
Matsumoto K; Saida T
Nihon Rinsho; 2006 Jul; 64(7):1321-6. PubMed ID: 16838651
[TBL] [Abstract][Full Text] [Related]
2. Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group.
Richtig E; Soyer HP; Posch M; Mossbacher U; Bauer P; Teban L; Svolba G; Wolf IH; Fritsch P; Zelger B; Volc-Platzer B; Gebhart W; Mischer P; Steiner A; Pachinger W; Hintner H; Gschnait F; Rappersberger K; Pilarski P; Pehamberger H;
J Clin Oncol; 2005 Dec; 23(34):8655-63. PubMed ID: 16260701
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose?
Schuchter LM
J Clin Oncol; 2004 Jan; 22(1):7-10. PubMed ID: 14665612
[No Abstract] [Full Text] [Related]
4. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
[TBL] [Abstract][Full Text] [Related]
5. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Hauschild A; Garbe C; Stolz W; Ellwanger U; Seiter S; Dummer R; Ugurel S; Sebastian G; Nashan D; Linse R; Achtelik W; Mohr P; Kaufmann R; Fey M; Ulrich J; Tilgen W
Br J Cancer; 2001 Apr; 84(8):1036-42. PubMed ID: 11308250
[TBL] [Abstract][Full Text] [Related]
6. The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma.
McClay EF; McClay ME; Monroe L; Baron PL; Cole DJ; O'Brien PH; Metcalf JS; Maize JC
Br J Cancer; 2000 Jul; 83(1):16-21. PubMed ID: 10883662
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
Daponte A; Ascierto PA; Gravina A; Melucci MT; Palmieri G; Comella P; Cellerino R; DeLena M; Marini G; Comella G;
Cancer; 2000 Dec; 89(12):2630-6. PubMed ID: 11135225
[TBL] [Abstract][Full Text] [Related]
8. Randomized adjuvant therapy trials in melanoma: surgical and systemic.
Eggermont AM; Gore M
Semin Oncol; 2007 Dec; 34(6):509-15. PubMed ID: 18083374
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant therapy of melanoma.
Shah GD; Chapman PB
Cancer J; 2007; 13(3):217-22. PubMed ID: 17620773
[TBL] [Abstract][Full Text] [Related]
10. The current EORTC Melanoma Cooperative Group adjuvant trial programme on malignant melanoma: prognosis versus efficacy, toxicity and costs.
Eggermont AM
Melanoma Res; 1997 Aug; 7 Suppl 2():S127-31. PubMed ID: 9578428
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant therapy of malignant melanoma.
Dickler MN; Coit DG; Meyers ML
Surg Oncol Clin N Am; 1997 Oct; 6(4):793-812. PubMed ID: 9309094
[TBL] [Abstract][Full Text] [Related]
12. Present status and future prospects for adjuvant therapy of melanoma: time to build upon the foundation of high-dose interferon alfa-2b.
Moschos SJ; Kirkwood JM; Konstantinopoulos PA
J Clin Oncol; 2004 Jan; 22(1):11-4. PubMed ID: 14665613
[No Abstract] [Full Text] [Related]
13. New approaches to the systemic treatment of melanoma.
Chowdhury S; Vaughan MM; Gore ME
Cancer Treat Rev; 1999 Oct; 25(5):259-70. PubMed ID: 10544070
[TBL] [Abstract][Full Text] [Related]
14. What can we learn from phase II adjuvant trials in melanoma?
Keilholz U; Suciu S; Eggermont AM
Br J Cancer; 2000 Jul; 83(1):6-7. PubMed ID: 10883660
[No Abstract] [Full Text] [Related]
15. Biochemotherapy of melanoma.
Keilholz U
Forum (Genova); 2003; 13(2):158-65; quiz 189. PubMed ID: 14732882
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha.
Lissoni P; Vaghi M; Ardizzoia A; Malugani F; Fumagalli E; Bordin V; Fumagalli L; Bordoni A; Mengo S; Gardani GS; Tancini G
In Vivo; 2002; 16(2):93-6. PubMed ID: 12073777
[TBL] [Abstract][Full Text] [Related]
17. [Aranoza -- a new Russian antineoplastic drug].
Gorbunova VA; Orel NF; Semina OV; Egorov GN; Borodkina AG; Manziuk LV
Vopr Onkol; 2001; 47(6):672-5. PubMed ID: 11826486
[TBL] [Abstract][Full Text] [Related]
18. [Long-term results of adjuvant chemotherapy after therapeutic lymph node dissection in patients with cutaneous malignant melanoma].
Kretschmer L; Helmbold P; Emmert S; Marsch WC
Hautarzt; 2002 Aug; 53(8):536-41. PubMed ID: 12221468
[TBL] [Abstract][Full Text] [Related]
19. Outpatient chemoimmunotherapy for the treatment of metastatic melanoma.
Thompson JA; Gold PJ; Fefer A
Semin Oncol; 1997 Feb; 24(1 Suppl 4):S44-8. PubMed ID: 9122734
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant therapy of cutaneous melanoma -- current status.
Hansson J
Acta Oncol; 2006; 45(4):369-72. PubMed ID: 16760171
[No Abstract] [Full Text] [Related]
[Next] [New Search]
